Nakano, Hiroto
Kirino, Yohei http://orcid.org/0000-0002-9488-661X
Takeno, Mitsuhiro
Higashitani, Kana
Nagai, Hideto
Yoshimi, Ryusuke
Yamaguchi, Yukie
Kato, Ikuma
Aoki, Ichiro
Nakajima, Hideaki
Funding for this research was provided by:
Japanese Society for the Promotion of Science Grants-in-Aid for Scientific Research (26713036, 26461469, 26461468, 16K19085)
Yokohama Foundation for Advancement of Medical Science
The Naito Memorial Foundation
The Uehara Memorial Foundation
Japan Intractable Diseases Research Foundation
Japan Rheumatic Disease Foundation
Takeda Science Foundation
Article History
Received: 13 November 2017
Accepted: 30 April 2018
First Online: 12 June 2018
Ethics approval and consent to participate
: The study protocol and genetic analyses were approved by Yokohama City University Ethics Board (A140327015 and B131107009). All of the human samples were used after written informed consent was obtained.
: MT serves as an advisor for the apremilast clinical trial for Celgene.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.